A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

Model scores of the 29,894 trials active now.

Model score 35% for any early termination, 23% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiaamltransplantallogeneictherapy
  Phrases that lowered it: the effecteffect ofscreeningchildrenabuse
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Drug's FAERS reports with a death: 33.9% (raises risk) · Drug's FDA history
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 60 (raises risk) · Who can join
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports marked serious: 78.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 3431 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab NCT03286114 · started 2017 · scored riskier than 80% of active trials terminated
• Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts NCT03160079 · started 2017 · scored riskier than 90% of active trials completed
• Nivolumab in AML in Remission at High Risk for Relapse NCT02532231 · started 2015 · scored riskier than 74% of active trials completed
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia NCT02767934 · started 2017 · scored riskier than 72% of active trials terminated
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia NCT02996474 · started 2016 · scored riskier than 50% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.